Skip to main content

On This Page

← AI Financial News

Lazard – 2025-12-08 - Increase Confidence 7/10

2 min read $LAZ
Share

These articles are AI-generated summaries. Please check the original sources for full details.

LAZLazard, Inc.
$54.75-1.42 (-2.53%)
$57$52$46Sep 8Oct 22Dec 5
52W High: $57.2252W Low: $46.24Volume: 1.10M
NYSE
Prediction (12/22/2025):High: $58.07Low: $31.97Ref Price: $50.66
This chart shows historical data as of December 5, 2025. Not updated in real-time.

LAZ – Increase in Days/Weeks

Lazard posted a revenue growth rate of 16.23% as of June 30, 2025, signaling strong demand for its advisory and asset management services. With the next earnings report due January 29, 2026, and recent EPS beats fueling momentum, investor sentiment is poised for a positive re-rating in the near term.

Why This Matters

Lazard’s 16.23% revenue growth and $697 million in trailing free cash flow reflect operational strength in a high-margin business model, particularly amid resilient M&A and restructuring activity globally. With the stock trading below analysts’ average price target of $60.40—implying 18.62% upside—and a favorable dividend yield of 3.65%, the current price of $50.66 appears undervalued ahead of the next earnings release, making it a compelling near-term opportunity.

Key Insights

  • Revenue Growth: +16.23% YoY as of June 30, 2025
  • News Impact: Upcoming earnings (Jan 29, 2026) and recent EPS beat (+$0.13) signal continued momentum
  • Risk/Offset: High debt/equity ratio (2.98) above industry average increases leverage risk in volatile markets

Practical Implications

  • Bull Case: EPS beat and raised guidance in next report → move toward $56–$58 range in 2–3 weeks
  • Bear Case: Macro-driven M&A slowdown or higher rates → stock retests $47–$48 support
  • Confidence: 7/10 – Strong fundamentals and catalyst alignment outweigh leverage concerns

Prediction: increase

Reference:

Continue reading

Next article

Legend Biotech – 2025-12-08 - Increase Confidence 6/10

Related Content